Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers-Reference-Cited by-同舟云学术

Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers

Published:2015-09-22 Issue:1 Volume:6 Page:
ISSN:2041-1723
Container-title:Nature Communications
language:en
Short-container-title:Nat Commun

Author:

Misale Sandra,Bozic Ivana,Tong Jingshan,Peraza-Penton Ashley,Lallo Alice,Baldi Federica,Lin Kevin H.,Truini Mauro,Trusolino Livio,Bertotti Andrea,Di Nicolantonio Federica^ORCID,Nowak Martin A.,Zhang Lin,Wood Kris C.,Bardelli Alberto

Publisher

Springer Science and Business Media LLC

Subject

General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry

Link

http://www.nature.com/articles/ncomms9305.pdf

Reference35 articles.

1. Vogelstein, B. & Kinzler, K. W. Cancer genes and the pathways they control. Nat. Med. 10, 789–799 (2004).

2. Pines, G., Köstler, W. J. & Yarden, Y. Oncogenic mutant forms of EGFR: lessons in signal transduction and targets for cancer therapy. FEBS Lett. 584, 2699–2706 (2010).

3. Weinstein, I. B. Cancer. Addiction to oncogenes--the achilles heal of cancer. Science 297, 63–64 (2002).

4. Misale, S., Di Nicolantonio, F., Sartore-Bianchi, A., Siena, S. & Bardelli, A. Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution. Cancer Discov. 4, 1269–1280 (2014).

5. Chong, C. R. & Jänne, P. A. The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat. Med. 19, 1389–1400 (2013).

Cited by 100 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Signaling dynamics in coexisting monoclonal cell subpopulations unveil mechanisms of resistance to anti-cancer compounds;Cell Communication and Signaling;2024-07-26

2. Comparison of primary and passaged tumor cell cultures and their application in personalized medicine;Exploration of Targeted Anti-tumor Therapy;2024-06-17

3. Mediator kinase inhibition impedes transcriptional plasticity and prevents resistance to ERK/MAPK-targeted therapy in KRAS-mutant cancers;npj Precision Oncology;2024-05-31

4. MerTK Drives Proliferation and Metastatic Potential in Triple-Negative Breast Cancer;International Journal of Molecular Sciences;2024-05-08

5. Unveiling acquired resistance to anti-EGFR therapies in colorectal cancer: a long and winding road;Frontiers in Pharmacology;2024-04-22